Pentokey Organy India Ltd

Certificate receipt

• Certificate under Regulation 74(5) received from Datamatics Business Solutions Ltd (RTA) for quarter ended 30 September 2026.

Pentokey Organy India Ltd — Trading Window closed from 1st October, 2026; shall re-open 48 hours after the unaudited Financial Results of the Company for the Quarter ended 30th September, 2026 become generally available.

AGM Details

• AGM held on 26 September 2026 at 3:00 PM via VC/OAVM.
• Remote e-voting conducted 23–25 September 2026; cut-off date 19 September 2026.
• Voting results announced on 28 September 2026.

Key Resolutions

• Adoption of audited financial statements and reports (Ordinary).
• Re-appointment of Arun Goenka as Director by rotation (Ordinary).
• Appointment of Kavita Kailash Bohra as Independent Director (Special).

Voting Results

• Item 1 passed with 99.999% in favour.
• Item 2 passed with 99.999% in favour.
• Item 3 passed as Special with 99.998% in favour.

Dividend

• No dividend proposed or declared.

Director Changes

• Arun Goenka re-appointed as director by rotation.
• Kavita Bohra appointed as Independent Director.

AGM details

• AGM held on 26 September 2026 at 3:00 PM via VC/OAVM.
• Quorum: 35 members attended via VC.

Ordinary business

• Adopt Audited financial statements for year ended March 31, 2026 and related reports.
• Reappointment of Arun Goenka retiring by rotation.

Special business

• Appoint Kavita Kailash Bohra as Non-Executive Independent Director.

Voting results

• Scrutinizer's report to be submitted within 2 working days.
• Results to be announced by the company and notified to BSE and published on websites.

Financial snapshot

• Revenue from operations (gross): ₹209.00 Lakhs.
• Total income: ₹249.80 Lakhs.
• Profit before tax: ₹20.32 Lakhs.
• Profit after tax: ₹20.32 Lakhs.
• Total comprehensive income: ₹23.80 Lakhs.
• Earnings per share: ₹0.32 (basic and diluted).

Margins & profitability

• Operating margin: 2.10%.
• Net profit margin: 8.13%.
• ROE/ROCE: 2.10%.
• Dividend not proposed for 2025-26.

Capital structure & liquidity

• Net worth: ₹969.52 Lakhs; equity capital: ₹627.26 Lakhs.
• Gearing ratio: -3.67%.
• Net debt: -₹36.96 Lakhs.
• Cash and cash equivalents: ₹11.96 Lakhs; bank balances: ₹592.47 Lakhs.

Operations & geography

• Domestic sales: ₹194.41 Lakhs; export sales: ₹14.59 Lakhs; total: ₹209.00 Lakhs.
• Single segment: Trading of Pharmaceutical Products.
• Inventory: ₹32.74 Lakhs; trade receivables: ₹116.33 Lakhs; cash: ₹11.96 Lakhs.
• No separate product lines disclosed.

Governance & audit

• Secretarial audit: no qualification; GST/Tax delays noted.
• Statutory auditor: Verma Mehta & Associates; term to 2028; independence confirmed.
• Secretarial auditor: Gajab Maheshwari; no qualifications.
• Independent Director Kavita Bohra appointed for five years from 13 Aug 2026.

Shareholder matters & AGM

• Dividend not proposed for 2025-26.
• Promoter holdings: Purshottam Kejriwal 35.72%; others listed.
• Equity shares issued: 62,72,629.
• 39th AGM: 26 Sep 2026 via VC/OAVM.

Outlook & risks

• Markets opened up; management targets substantial growth.
• Risks include macroeconomic and regulatory factors.
• Internal controls robust; no material fraud reported.

AGM Details

• AGM date set for 26 September 2026 at 3:00 PM.
• Venue: video conference/other audio-visual means.

Appointment details

• Board approved appointment of Kavita Kailash Bohra as Additional Non-Executive Independent Director.
• Effective 13 August 2026; term of 5 years, subject to shareholder approval.
• Appointment recommended by the Nomination & Remuneration Committee.
• Not debarred from holding office by SEBI/MCA or statutory authority.
• Not related to any existing director; maintains independent status.
• Profile: Chartered Accountant with 8+ years post-qualification experience; ICAI Fellow; COP since 2018.

Financial results and auditor's review

• Board approved unaudited standalone results for quarter ended 30 June 2026.
• Limited review report from statutory auditors accompanying the results.
• Audit report states no material misstatement and compliance with Ind AS.

Meeting Details

• Board meeting scheduled for 13 August 2026; time and venue not disclosed.

Key Agenda Items

• Consider and approve unaudited quarterly financial results for quarter ended 30 June 2026.

Other Notes

• Trading window currently closed; will reopen 48 hours after results are generally available.
• Intimation uploaded on the company's website.